Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 1.27 CAD Market Closed
Market Cap: 367.2m CAD

Spectral Medical Inc
Effect of Foreign Exchange Rates

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Spectral Medical Inc
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Spectral Medical Inc
TSX:EDT
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Effect of Foreign Exchange Rates
$15k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-18%
Repare Therapeutics Inc
NASDAQ:RPTX
Effect of Foreign Exchange Rates
-$7k
CAGR 3-Years
51%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Effect of Foreign Exchange Rates
-$595k
CAGR 3-Years
43%
CAGR 5-Years
-27%
CAGR 10-Years
21%
Willow Biosciences Inc
TSX:WLLW
Effect of Foreign Exchange Rates
CA$26k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Spectral Medical Inc
Glance View

Market Cap
367.2m CAD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDT Intrinsic Value
1 CAD
Overvaluation 22%
Intrinsic Value
Price

See Also

Back to Top